Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis


Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Aim(s): Survival comparison of matched metastatic grade 1 or 2 NETs with and without SST2 expression.

Materials and methods: Retrospective cohort analysis. SST2-negativity was defined as tumor uptake below that of the liver on somatostatin receptor scintigraphy. Patients that underwent PRRT were excluded.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

To read the full abstract, please log into your ENETS Member account.